Samples n | 0 | 1 | 2 | 3 | 4 | 5 | 6 | |
Normal | 13 | 0 | 13 | 0 | 0 | 0 | 0 | 0 |
Hyperplasia | 19 | 4 | 15 | 0 | 0 | 0 | 0 | 0 |
Metaplasia | 16 | 0 | 9 | 1 | 4 | 1 | 0 | 1 |
Mild dysplasia | 10 | 0 | 10 | 0 | 0 | 0 | 0 | 0 |
Moderate dysplasia | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Severe dysplasia | 10 | 1 | 2 | 1 | 0 | 0 | 4 | 2 |
CIS | 14 | 2 | 0 | 0 | 0 | 6 | 6 | 0 |
Microinvasive tumour | 11 | 2 | 0 | 0 | 0 | 3 | 2 | 4 |
The global EGF-R score was obtained by the sum of the positivity score and of the intensity score
0: EGF-R positivity and intensity of 0
1: EGF-R positivity or intensity of 0 and EGF-R intensity or positivity of 1
2: EGF-R positivity and intensity of 1
3: EGF-R positivity or intensity of 1 and EGF-R intensity or positivity of 2
4: EGF-R positivity and intensity of 2 or EGF-R positivity or intensity of 1 and EGF-R intensity or positivity of 3
5: EGF-R positivity or intensity of 2 and EGF-R intensity or positivity of 3
6: EGF-R positivity and intensity of 3
CIS: carcinoma in situ